Completion of Patient Recruitment for International TIGER Study

Brussels, 19 December 2022 – EORTC and  Alliance for Clinical Trials in Oncology are pleased to announce that the target accrual in A031102/EORTC1407 TIGER study has been reached.

A031102/EORTC 1407 (TIGER) is an international phase III trial that seeks to establish the standard of care for second-line (also called initial salvage) chemotherapy in patients with advanced germ cell tumors (GCT). TIGER compares initial salvage conventional-dose chemotherapy (CDCT) with the TIP regimen vs. high-dose chemotherapy and autologous stem cell transplant (HDCT/ASCT) with the TI-CE regimen with a primary endpoint of overall survival. The completion of patient recruitment is a major milestone for this groundbreaking trial.

EORTC would like to thank the collaborating groups who have supported this trial, including our funding partner Movember. Without them, this trial would not have been possible in Europe.

“The TIGER trial is significant because collaboration between the Alliance/NCI and EORTC demonstrates that it is possible to conduct investigator-initiated randomized clinical trials in rare malignancies through the cooperative group mechanism in the absence of pharmaceutical company support. To our knowledge, TIGER is the first transatlantic cooperative group-led randomized trial conducted in GCT.  This landmark study was open at 63 enters within 13 countries across 3 continents (North America, Europe, and Australia/New Zealand), and has helped pave the way for additional CTEP/NCI-led trials in other rare malignancies via collaboration with EORTC or other international partners.”

– Dr Darren R. Feldman, Study Chair, Memorial Sloan Kettering Cancer Center, US

“The EORTC demonstrated its ability to deliver complex trials in rare cancer. This template can be used in future trials facilitating clinical cancer research.”

– Dr Thomas Powles, EORTC Study Chair, Barts Cancer Institute, UK

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023